Sorted libraries of error-free long oligonucleotides

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$200,625.00
Award Year:
2013
Program:
SBIR
Phase:
Phase I
Contract:
1R43DK099853-01
Award Id:
n/a
Agency Tracking Number:
R43DK099853
Solicitation Year:
2013
Solicitation Topic Code:
NIDDK
Solicitation Number:
PA12-088
Small Business Information
80 WEBSTER ST, WORCESTER, MA, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
9796223
Principal Investigator:
ERNEST GROMAN
(508) 770-1190
EVGroman@aol.com
Business Contact:
ERNEST GROMAN
(508) 770-1190
EVGroman@aol.com
Research Institute:
Stub




Abstract
DESCRIPTION (provided by applicant): Iron deficiency is frequently encountered in chronic kidney disease (CKD) patients and many other populations. Current oral iron formulations are poorly tolerated. Injectable iron preparations are difficult to administer, costly and have serious adverse reactions. Therefore, a highly absorbable, well tolerated oral iron supplement for the treatment of anemia associated with chronic kidney disease (CKD) is needed to complement erythropoiesis-stimulating agents. Our ironreplacement agent will have the following attributes: 1) oral delivery with minimal adverse events, 2) efficient intestinal transit with vascular system entry, 3) liver targeting where the iron is released to normal iron stores and 4) cost-effective manufacture providing savings to the medical economy. Our Phase I SBIR application is designed to synthesize prototype products fitting this description. This will be accomplished by applying the company's nano-technology expertise to develop a stable iron oxidecolloid having a surface coating to permit intestinal transport while protecting against bacterial bloom within th gut. Our proposed product is expected to be the first commercially feasible oral iron replacement therapy that can be safely self-administrated by the patient. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: This project will develop an oral iron supplement to more effectively treat iron deficient patients, a common occurrence in chronic kidney disease. The advantage of this product will be its low cost and the easy-of-use. This product is expected to be the first commercially feasible method that will allow patients to self-treat iron deficiency.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government